Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602467 | 0.92 | KDM4E (0.46) | NPC1KMT2AGRIN2BRAB9ACNR1 | |
| SCHEMBL3591928 | 0.91 | GRIN2B (0.46) | NPC1KMT2AGRIN2BRAB9ACNR1 | |
| SCHEMBL3588047 | 0.90 | GRIN2B (0.52) | NTSR1FAAHGRIN2BRAB9ANPY5R | |
| SCHEMBL3602171 | 0.86 | KDM4E (0.43) | KMT2ANTSR1FAAHGRIN2BNPY5R | |
| SCHEMBL3604146 | 0.85 | KDM4E (0.45) | NPC1KMT2AGRIN2BRAB9ANPY5R | |
| SCHEMBL3600906 | 0.84 | GRIN2B (0.47) | NPC1KMT2ANTSR1GRIN2B | |
| SCHEMBL3644326 | 0.84 | KDM4E (0.48) | GRIN2B | |
| SCHEMBL3595148 | 0.83 | KDM4E (0.45) | NPC1GRIN2BNPY5R | |
| SCHEMBL3598451 | 0.83 | ALDH1A1 (0.45) | KMT2ANTSR1GRIN2B | |
| SCHEMBL3596255 | 0.83 | NPC1 (0.46) | NPC1KMT2ANTSR1FAAHGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | NPC1 334/4885KMT2A 3838/4885NTSR1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.